Free Trial
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

Akari Therapeutics logo
$0.93 -0.05 (-4.74%)
Closing price 10/2/2025 03:59 PM Eastern
Extended Trading
$0.96 +0.03 (+3.03%)
As of 05:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Akari Therapeutics Stock (NASDAQ:AKTX)

Advanced

Key Stats

Today's Range
$0.93
$0.98
50-Day Range
$0.66
$1.14
52-Week Range
$0.57
$3.70
Volume
37,289 shs
Average Volume
466,269 shs
Market Capitalization
$30.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.30
Consensus Rating
Buy

Company Overview

Akari Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

AKTX MarketRank™: 

Akari Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 566th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Akari Therapeutics has a consensus price target of $3.30, representing about 253.4% upside from its current price of $0.93.

  • Amount of Analyst Coverage

    Akari Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Akari Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    0.26% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently increased by 244.72%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Akari Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akari Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.26% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently increased by 244.72%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Akari Therapeutics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Akari Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    Only 1 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Akari Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,540.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    38.10% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 5.06% of the stock of Akari Therapeutics is held by institutions.

  • Read more about Akari Therapeutics' insider trading history.
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AKTX Stock News Headlines

U.S. Government Sparking Crypto Rally
U.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised to benefit from this massive shift inside my Bull Run Millionaire Blueprint.tc pixel
Akari Therapeutics (AKTX) to Release Earnings on Thursday
See More Headlines

AKTX Stock Analysis - Frequently Asked Questions

Akari Therapeutics' stock was trading at $1.22 at the beginning of the year. Since then, AKTX stock has decreased by 23.5% and is now trading at $0.9337.

Akari Therapeutics PLC (NASDAQ:AKTX) issued its earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

Akari Therapeutics's stock reverse split on the morning of Thursday, August 17th 2023.The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE).

Company Calendar

Last Earnings
3/31/2020
Today
10/02/2025
Next Earnings (Estimated)
11/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKTX
CIK
1541157
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$1.60
Potential Upside/Downside
+253.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.79 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-78.03%
Return on Assets
-31.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.84 per share
Price / Book
1.11

Miscellaneous

Outstanding Shares
32,620,000
Free Float
20,189,000
Market Cap
$30.46 million
Optionable
Not Optionable
Beta
0.36
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:AKTX) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners